These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Blood substitute oxygen carriers. Abel WG N Y State J Med; 1982 Sep; 82(10):1429-33. PubMed ID: 6958997 [No Abstract] [Full Text] [Related]
43. Success in the radical resection of esophageal cancer with artificial blood infusion: case report. Mitsuno T; Kawa Y; Kita A; Kohno N Int Surg; 1981; 66(4):355-8. PubMed ID: 7345051 [TBL] [Abstract][Full Text] [Related]
44. Clinical potential of intravenously administered perfluorocarbons. Habler O; Kleen M; Messmer K Acta Anaesthesiol Scand Suppl; 1997; 111():256-8. PubMed ID: 9421036 [No Abstract] [Full Text] [Related]
46. The use of perfluorochemicals in the treatment of acute cerebral ischemia. Peerless SJ Prog Clin Biol Res; 1983; 122():353-62. PubMed ID: 6410404 [No Abstract] [Full Text] [Related]
47. Perfluorocarbons in the twenty-first century: clinical applications as transfusion alternatives. Spence RK Artif Cells Blood Substit Immobil Biotechnol; 1995; 23(3):367-80. PubMed ID: 7493058 [TBL] [Abstract][Full Text] [Related]
48. Treatment of severe anaemia with perfluorocarbon blood substitutes: a clinical overview. Nyberg SL; Cerra FB Clin Intensive Care; 1991; 2(4):226-32. PubMed ID: 10149096 [No Abstract] [Full Text] [Related]
49. Influence of Fluosol-DA infusion on the complement activation and on the blood level of histamine in man. Fukushima K; Nakamura M; Hinuma K Prog Clin Biol Res; 1983; 122():291-8. PubMed ID: 6878373 [No Abstract] [Full Text] [Related]
51. Hemoglobin solutions as blood substitutes: an overview. Bellelli A; Brunori M Ann Ital Med Int; 1986 Dec; 1(4):275-80. PubMed ID: 3079371 [No Abstract] [Full Text] [Related]
52. Artificial oxygen carriers as red blood cell substitutes: a selected review and current status. Kim HW; Greenburg AG Artif Organs; 2004 Sep; 28(9):813-28. PubMed ID: 15320945 [TBL] [Abstract][Full Text] [Related]
53. Physiological effects of perfluorocarbon blood substitutes. Lowe KC; Bollands AD Med Lab Sci; 1985 Oct; 42(4):367-75. PubMed ID: 3908874 [No Abstract] [Full Text] [Related]
54. Oxygen therapeutics: perfluorocarbons and blood substitute safety. Cohn CS; Cushing MM Crit Care Clin; 2009 Apr; 25(2):399-414, Table of Contents. PubMed ID: 19341916 [TBL] [Abstract][Full Text] [Related]
55. Inflammation induced by perfluorocarbon liquid: intra- and postoperative use. Figueroa MS; Casas DR Biomed Res Int; 2014; 2014():907816. PubMed ID: 24783224 [TBL] [Abstract][Full Text] [Related]
56. [Changes in clinico-immunological indices of experimental allergic encephalomyelitis after treatment with perftoran]. Zhitnukhin IuL; Litvinenko IV; Bisaga GN; Odinak MM Biull Eksp Biol Med; 1997 Mar; 123(3):315-8. PubMed ID: 9162244 [No Abstract] [Full Text] [Related]
57. Blood substitutes based on modified hemoglobin and fluorochemicals. Chang TM; Farmer M; Geyer RP; Moss G ASAIO Trans; 1987; 33(4):819-23. PubMed ID: 3426865 [No Abstract] [Full Text] [Related]
58. Blood substitute being developed. AIDS Patient Care STDS; 2000 Sep; 14(9):521. PubMed ID: 11051639 [No Abstract] [Full Text] [Related]
59. Perfluorocarbons: future clinical possibilities. Clark MC; Weiman DS; Pate JW; Gir S J Invest Surg; 1997; 10(6):357-65. PubMed ID: 9654392 [TBL] [Abstract][Full Text] [Related]